Wegovy vs Ozempic: Head-to-Head Efficacy Comparison

Same Molecule, Different Missions

Wegovy and Ozempic both deliver semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. The difference is dose ceiling and labeled purpose. Wegovy titrates up to 2.4 mg weekly for chronic weight management, while Ozempic caps at 2.0 mg weekly for type 2 diabetes (T2D) glycemic control.

The FDA approved Ozempic in December 2017 based on the SUSTAIN clinical trial program, which enrolled patients with T2D and measured HbA1c reduction as the primary endpoint [1]. Weight loss was a secondary outcome. Wegovy received approval in June 2021 following the STEP trial program, which enrolled adults with obesity or overweight (with comorbidities) and measured percentage body-weight change as the primary endpoint [2].

Because the two products were tested in different populations, at different doses, with different primary endpoints, cross-trial comparisons require caution. A 2022 systematic review in Diabetes, Obesity and Metabolism noted that indirect comparisons across GLP-1 RA trials are limited by differences in baseline BMI, diabetes status, and trial duration [3]. No published randomized controlled trial has compared Wegovy 2.4 mg directly against Ozempic 2.0 mg in the same patient cohort.

Weight-Loss Efficacy: What the Trials Show

Wegovy's weight-loss data comes primarily from the STEP program. In STEP-1 (N=1,961), adults without diabetes who received semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks, compared with 2.4% in the placebo group [2]. The results were striking: 86.4% of participants on semaglutide achieved at least 5% weight loss, and 69.1% achieved at least 10%.

Ozempic's weight data comes from the SUSTAIN trials, where weight loss was a secondary outcome. In SUSTAIN-7 (N=1,201), patients with T2D receiving semaglutide 1.0 mg lost 6.5 kg at 40 weeks, versus 3.0 kg with dulaglutide 1.5 mg [1]. SUSTAIN-6 (N=3,297) reported a mean weight loss of 4.3 kg with semaglutide 1.0 mg over 104 weeks in a cardiovascular outcomes trial population [4].

The dose gap explains much of the difference. Wegovy's 2.4 mg dose is 20% higher than Ozempic's maximum approved 2.0 mg, and the STEP trials enrolled a population selected specifically for obesity, where absolute weight-loss potential tends to be greater. Patients in SUSTAIN trials had lower mean baseline BMIs and were taking concurrent diabetes medications that may blunt weight change.

Dr. Robert Kushner, a professor of medicine at Northwestern University Feinberg School of Medicine who served as an investigator in the STEP program, stated: "The magnitude of weight loss seen with semaglutide 2.4 mg approaches what we previously only achieved with bariatric surgery in some patient subgroups" [2].

Glycemic Control: Where Ozempic Leads by Indication

Ozempic was built for glucose lowering. Its label advantage is clear in patients managing T2D. In SUSTAIN-7, semaglutide 1.0 mg reduced HbA1c by 1.8 percentage points at 40 weeks, outperforming dulaglutide 1.5 mg (1.4 percentage-point reduction) [1]. SUSTAIN-6 demonstrated sustained HbA1c reductions of 1.1 percentage points over two years [4].

Wegovy's trial program did not enroll patients with T2D as a primary population (STEP-1 excluded them). STEP-2 (N=1,210) did include adults with T2D and obesity, and semaglutide 2.4 mg produced a 9.6% mean weight loss at 68 weeks versus 3.4% with placebo [5]. HbA1c fell by 1.6 percentage points in the semaglutide group. These STEP-2 results suggest that the higher Wegovy dose could match or exceed Ozempic's glycemic benefit, but the trial was designed around weight loss, not glucose endpoints.

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 RAs with proven cardiovascular benefit as preferred second-line agents for T2D after metformin [6]. Ozempic (semaglutide) is specifically named. Wegovy is not indicated for T2D, meaning prescribers who want semaglutide for blood sugar control should use Ozempic or its oral formulation, Rybelsus.

Cardiovascular Outcomes

The SELECT trial (N=17,604) established cardiovascular benefit for semaglutide 2.4 mg (the Wegovy dose) in adults with overweight or obesity and established cardiovascular disease but without diabetes [7]. Over a median 39.8 months, semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 20% compared with placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90, P<0.001) [7].

This was a landmark result. SELECT was the first trial to show that a GLP-1 RA reduces cardiovascular events in patients selected for obesity rather than diabetes. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity cites SELECT as evidence supporting semaglutide 2.4 mg for cardiovascular risk reduction in eligible patients [8].

Ozempic's cardiovascular data comes from SUSTAIN-6, which was a noninferiority trial in T2D patients. SUSTAIN-6 showed a statistically significant 26% reduction in MACE with semaglutide versus placebo (HR 0.74, 95% CI 0.58 to 0.95), though the trial was not powered as a superiority study and enrolled only 3,297 patients [4]. The doses tested were 0.5 mg and 1.0 mg.

Both products share the same molecule's cardiovascular signal, but the strength of evidence differs by indication and dose. For obesity-specific cardiovascular protection, Wegovy at 2.4 mg has the stronger dataset.

Dose Titration and Tolerability

Both drugs follow a stepwise titration to reduce gastrointestinal side effects. Wegovy's schedule spans 16 weeks: 0.25 mg for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each step lasting four weeks [9]. Ozempic's titration is shorter. Patients start at 0.25 mg for four weeks, increase to 0.5 mg, and may later escalate to 1.0 mg or 2.0 mg depending on glycemic response [10].

Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) are the most common reason patients discontinue either product. In STEP-1, 44.2% of participants on semaglutide 2.4 mg reported nausea at some point during the trial, though most episodes were mild to moderate and occurred during dose escalation [2]. In SUSTAIN-7, nausea rates were 21.2% with semaglutide 1.0 mg [1]. The higher Wegovy dose appears to carry a proportionally higher GI side-effect burden, which aligns with the general dose-response relationship of GLP-1 RAs.

Discontinuation rates due to adverse events were 7.0% in the STEP-1 semaglutide arm [2] and 5.8% in the SUSTAIN-7 semaglutide 1.0 mg arm [1]. These numbers are close enough that tolerability alone is unlikely to be the deciding factor for most patients.

Dr. Ania Jastreboff, director of the Yale Obesity Research Center and lead author of several semaglutide trials, has noted: "The GI side effects of semaglutide are dose-dependent and generally manageable with proper titration. Most patients who complete the escalation period tolerate the maintenance dose well" [2].

Cost, Coverage, and Real-World Access

Both Wegovy and Ozempic carry wholesale acquisition costs exceeding $1,300 per month without insurance. Coverage varies dramatically by payer. Commercial plans increasingly cover Ozempic for T2D (it is on most formularies as a preferred GLP-1 RA), but many plans exclude Wegovy for weight management or impose restrictive prior authorization criteria [11].

Medicare Part D covers Ozempic for T2D but historically did not cover anti-obesity medications. The Treat and Reduce Obesity Act, if passed, would change this. As of early 2026, CMS has expanded coverage for semaglutide 2.4 mg under Part D for patients with obesity and cardiovascular disease following the SELECT trial data [12].

Novo Nordisk's savings programs may reduce out-of-pocket costs for commercially insured patients, but cash-pay prices remain high. Some patients and clinicians use Ozempic off-label for weight loss at doses of 1.0 or 2.0 mg because it may be easier to obtain through insurance. This practice is common but unsupported by the labeled indication, and patients may not achieve the same degree of weight loss as seen with the full 2.4 mg Wegovy dose.

Who Should Use Which Product

The choice between Wegovy and Ozempic depends on the clinical indication, not on molecular preference (since both are semaglutide). The Endocrine Society's 2024 guideline and the American Gastroenterological Association's 2024 clinical practice update both frame the decision around diagnosis [8][13].

For adults with obesity (BMI ≥30) or overweight (BMI ≥27 with a weight-related comorbidity) seeking maximal weight loss: Wegovy 2.4 mg is the indicated product. STEP-1 supports this with 14.9% mean body-weight reduction [2]. For patients with T2D who need improved glycemic control and will also benefit from weight loss: Ozempic is the labeled choice, supported by the SUSTAIN program's HbA1c and cardiovascular data [1][4].

Patients with both T2D and obesity may face a coverage-driven decision. Some endocrinologists prescribe Ozempic 2.0 mg for dual benefit, accepting slightly lower weight loss relative to Wegovy 2.4 mg in exchange for formulary access. This approach lacks randomized trial support comparing the two doses in the same T2D-plus-obesity population.

Weight Regain After Discontinuation

Weight regain after stopping semaglutide is a documented concern with both products. The STEP-1 extension study (STEP-4 withdrawal analysis) showed that participants who stopped semaglutide 2.4 mg after 68 weeks regained approximately two-thirds of their lost weight within one year [14]. The Endocrine Society guideline describes obesity as a chronic disease requiring long-term pharmacotherapy, similar to hypertension or hyperlipidemia [8].

No equivalent withdrawal data from the SUSTAIN program has been published for Ozempic at the 2.0 mg dose. Smaller observational studies suggest a similar pattern of HbA1c and weight rebound after GLP-1 RA discontinuation in T2D populations [15].

This means that for either product, treatment duration should be framed as long-term. Stopping semaglutide to "see what happens" predictably results in weight regain for most patients, regardless of whether they were taking Wegovy or Ozempic.

Cross-Trial Comparison Summary

Interpreting weight-loss differences between Wegovy and Ozempic requires acknowledging that the trials measured different things in different people. STEP-1 enrolled a younger, heavier population without diabetes and ran for 68 weeks. SUSTAIN-7 enrolled T2D patients with lower baseline BMIs and ran for 40 weeks. The dose difference (2.4 mg vs 1.0 mg in the key comparisons) is the most straightforward explanation for the efficacy gap.

A 2023 network meta-analysis in The Lancet pooled data from 28 GLP-1 RA trials (N=15,069) and found that semaglutide at the highest tested dose consistently ranked first for weight reduction among all GLP-1 RAs, with an estimated 12.4% placebo-adjusted weight loss at one year [16]. The analysis did not separate Wegovy from Ozempic by brand but confirmed the dose-response relationship.

For clinicians making formulary decisions, the data support a simple principle: higher semaglutide doses produce more weight loss, and the 2.4 mg dose has the strongest evidence for both weight reduction and cardiovascular event prevention in patients without diabetes. Patients with T2D who need glucose lowering should start with Ozempic's indicated dose range and titrate based on glycemic targets, with a potential switch to Wegovy 2.4 mg if weight management becomes the primary goal and insurance permits.